MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

2.68 1.52

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.65

Max

2.69

Chiffres clés

By Trading Economics

Revenu

-6.4M

-53M

Ventes

-9.6M

47M

BPA

-0.02

Marge bénéficiaire

-112.813

Employés

580

EBITDA

-28M

-49M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+72.28% upside

Dividendes

By Dow Jones

Prochains Résultats

6 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

106M

880M

Ouverture précédente

1.16

Clôture précédente

2.68

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 juil. 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 juil. 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 juil. 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Received All Required Authorizations

4 juil. 2025, 15:48 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 juil. 2025, 15:47 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Agreement Was Announced on Dec. 19

4 juil. 2025, 15:47 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 juil. 2025, 15:46 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 juil. 2025, 14:30 UTC

Acquisitions, Fusions, Rachats

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 juil. 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 juil. 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 juil. 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 juil. 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 juil. 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 juil. 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 juil. 2025, 12:30 UTC

Market Talk

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 juil. 2025, 12:15 UTC

Market Talk

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 juil. 2025, 12:13 UTC

Market Talk

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 juil. 2025, 12:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

72.28% hausse

Prévisions sur 12 Mois

Moyen 4.6 USD  72.28%

Haut 7 USD

Bas 2 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

4

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.